COLORADO DENVER UNIVERSITY OF

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pilot Study of Haloperidol to Treat Critical Illness Delirium

Phase 2

Completed

Conditions: Delirium
Critical Illness

First Posted Date: 2007-02-01

Last Posted Date: 2012-11-14

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 20

Registration Number: NCT00429676

Locations: 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

Phase 4

Completed

Conditions: Otitis Media

Interventions: Drug: dornase alfa (Pulmozyme®)

First Posted Date: 2007-01-08

Last Posted Date: 2015-03-27

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 40

Registration Number: NCT00419380

Locations: 🇺🇸
The Children's Hospital, Denver, Colorado, United States

Using Learning Teams for Reflective Adaptation for Diabetes and Depression

Not Applicable

Completed

Conditions: Type 2 Diabetes
Depression
Hypertension
Hyperlipidemia

Interventions: Behavioral: Standard CQI intervention
Behavioral: Self-directed practice comparison
Behavioral: Chronic Care Improvement (CCI) Intervention

First Posted Date: 2006-12-22

Last Posted Date: 2012-11-22

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1565

Registration Number: NCT00414986

Locations: 🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir disoproxil fumarate/Emtricitabine
Drug: Lopinavir/Ritonavir

First Posted Date: 2006-12-21

Last Posted Date: 2013-02-20

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 16

Registration Number: NCT00414518

Locations: 🇿🇼
University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸
University of Colorado Health Sciences Center, Denver, Colorado, United States

Ondansetron Reduce Vomiting Associated With Ketamine PSA

Not Applicable

Completed

Conditions: Conscious Sedation

Interventions: Drug: Ondansetron

First Posted Date: 2006-10-13

Last Posted Date: 2013-05-13

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 268

Registration Number: NCT00387556

Locations: 🇺🇸
The Childrens Hospital, Denver, Colorado, United States

Progression of Hematopoietic Diseases in Shanghai, China

Completed

Conditions: Hematologic Diseases

First Posted Date: 2006-08-16

Last Posted Date: 2013-07-23

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 10757

Registration Number: NCT00365014

Locations: 🇨🇳
Joint Sino-US Clinical and Molecular Laboratory (JCML), Shanghai, China

Molecular Epidemiology of Benzene-exposed Workers.

Completed

Conditions: Hematologic Diseases

Interventions: Other: Shanghai workers

First Posted Date: 2006-08-15

Last Posted Date: 2015-05-21

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 2000

Registration Number: NCT00364520

Locations: 🇨🇳
Joint Sino-US Clinical and Molecular Laboratory (JCML), Shanghai, China

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Phase 4

Completed

Conditions: Metabolic Syndrome
Insulin Resistance

First Posted Date: 2006-08-15

Last Posted Date: 2012-11-22

Lead Sponsor: University of Colorado, Denver

Registration Number: NCT00364221

Locations: 🇺🇸
University of Colorado at Denver and Health Sciences Center General Clinical Research Center, Denver, Colorado, United States

Evaluating the Effect of Neighborhood Environments on Cardiovascular Risk Factors

Completed

Conditions: Cardiovascular Diseases

First Posted Date: 2006-08-08

Last Posted Date: 2013-12-25

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1140

Registration Number: NCT00361673

Locations: 🇺🇸
University of Colorado Denver, Denver, Colorado, United States

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Erlotinib hydrochloride
Drug: Sirolimus

First Posted Date: 2006-07-18

Last Posted Date: 2014-04-14

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 25

Registration Number: NCT00353301

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy